GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cyclopharm Ltd (ASX:CYC) » Definitions » Price-to-Free-Cash-Flow

Cyclopharm (ASX:CYC) Price-to-Free-Cash-Flow : N/A (As of Jun. 07, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cyclopharm Price-to-Free-Cash-Flow?

As of today (2024-06-07), Cyclopharm's share price is A$1.595. Cyclopharm's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.08. Hence, Cyclopharm's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Cyclopharm's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Cyclopharm's highest Price-to-Free-Cash-Flow Ratio was 346.87. The lowest was 3.91. And the median was 13.71.

ASX:CYC's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 33.93
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Cyclopharm's Free Cash Flow per Share for the six months ended in Dec. 2023 was A$-0.07. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was A$-0.08.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 12.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -31.50% per year.

During the past 13 years, Cyclopharm's highest 3-Year average Free Cash Flow per Share Growth Rate was 107.00% per year. The lowest was -156.00% per year. And the median was -3.50% per year.


Cyclopharm Price-to-Free-Cash-Flow Historical Data

The historical data trend for Cyclopharm's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclopharm Price-to-Free-Cash-Flow Chart

Cyclopharm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cyclopharm Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cyclopharm's Price-to-Free-Cash-Flow

For the Medical Devices subindustry, Cyclopharm's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclopharm's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cyclopharm's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cyclopharm's Price-to-Free-Cash-Flow falls into.



Cyclopharm Price-to-Free-Cash-Flow Calculation

Cyclopharm's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.595/-0.083
=N/A

Cyclopharm's Share Price of today is A$1.595.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.08.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Cyclopharm  (ASX:CYC) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Cyclopharm Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cyclopharm's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclopharm (ASX:CYC) Business Description

Traded in Other Exchanges
N/A
Address
Unit 4, 1 The Crescent, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

Cyclopharm (ASX:CYC) Headlines

No Headlines